Compare · CRL vs ONMD
CRL vs ONMD
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and OneMedNet Corp (ONMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and ONMD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $14.21B, about 408.2x ONMD ($34.8M).
- CRL has been more active in the news (17 items in the past 4 weeks vs 6 for ONMD).
- CRL has more recent analyst coverage (25 ratings vs 0 for ONMD).
- Company
- Charles River Laboratories International Inc.
- OneMedNet Corp
- Price
- -
- -
- Market cap
- $14.21B
- $34.8M
- 1M return
- -
- -19.49%
- 1Y return
- -
- -15.46%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- 2021
- News (4w)
- 17
- 6
- Recent ratings
- 25
- 0
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Latest CRL
- Chief Executive Officer Girshick Birgit gifted 528 shares, decreasing direct ownership by 1% to 35,485 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M exercised 2,039 shares at a strike of $194.12 and sold $599,711 worth of shares (2,039 units at $294.12) as part of a pre-agreed trading plan (SEC Form 4)
- Director Andrews Nancy C exercised 573 shares at a strike of $164.30 and sold $163,443 worth of shares (573 units at $285.24) (SEC Form 4)
- Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
- Chief Executive Officer Girshick Birgit exercised 6,500 shares at a strike of $179.66 and sold $1,819,350 worth of shares (6,500 units at $279.90) as part of a pre-agreed trading plan (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M exercised 3,714 shares at a strike of $179.66 and sold $1,038,657 worth of shares (3,714 units at $279.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Charles River Laboratories International Inc.
- EVP, Corp Strategy & Develop Laplume Joseph W gifted 257 shares, decreasing direct ownership by 0.82% to 31,041 units (SEC Form 4)
- Director Foster James C exercised 28,733 shares at a strike of $179.66 and sold $7,901,575 worth of shares (28,733 units at $275.00) as part of a pre-agreed trading plan (SEC Form 4)
- SVP, Finance and CAO Knell Michael Gunnar sold $1,730,250 worth of shares (6,645 units at $260.38) and exercised 2,345 shares at a strike of $196.12, decreasing direct ownership by 27% to 11,852 units (SEC Form 4)
Latest ONMD
- SEC Form 424B3 filed by OneMedNet Corp
- SEC Form 424B3 filed by OneMedNet Corp
- SEC Form DEF 14A filed by OneMedNet Corp
- SEC Form 10-Q filed by OneMedNet Corp
- Director Kosasa Thomas bought $1,000,000 worth of shares (1,449,275 units at $0.69), increasing direct ownership by 8% to 18,538,150 units (SEC Form 4)
- SEC Form PRE 14A filed by OneMedNet Corp
- OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development
- OneMedNet Corp filed SEC Form 8-K: Shareholder Director Nominations, Other Events
- SEC Form 424B3 filed by OneMedNet Corp
- SEC Form EFFECT filed by OneMedNet Corp